Invex Therapeutics Ltd
ASX:IXC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
US |
|
Z
|
ZAZZ Energy of Sweden AB (publ)
STO:ZAZZ B
|
SE |
Invex Therapeutics Ltd
Cash from Operating Activities
Invex Therapeutics Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Invex Therapeutics Ltd
ASX:IXC
|
Cash from Operating Activities
-AU$650k
|
CAGR 3-Years
42%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Cash from Operating Activities
-AU$2.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Operating Activities
AU$17.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Operating Activities
AU$125.4m
|
CAGR 3-Years
227%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Operating Activities
-AU$54.8m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Cash from Operating Activities
-AU$7.3m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Invex Therapeutics Ltd
Glance View
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on the development and commercialisation of Presendin (Exenatide) for neurological conditions relating to raised intracranial pressure. The firm received written responses from the United States Food and Drug Administration (FDA) Division of Neurology relating to its proposed Phase III clinical trial design for Presendin in Idiopathic Intracranial Hypertension (IIH). Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. The firm focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The firm intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimized to treat different neurological conditions.
See Also
What is Invex Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-650k
AUD
Based on the financial report for Jun 30, 2025, Invex Therapeutics Ltd's Cash from Operating Activities amounts to -650k AUD.
What is Invex Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
17%
Over the last year, the Cash from Operating Activities growth was 73%. The average annual Cash from Operating Activities growth rates for Invex Therapeutics Ltd have been 42% over the past three years , 17% over the past five years .
